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Expression of hepcidin, a central regulator of systemic iron metabolism, is 
transcriptionally regulated by the bone morphogenetic protein (BMP) pathway. 
However, the factors other than the BMP pathway also participate in the regulation of 
hepcidin expression. In the present study, we show that serum treatment increased 
hepcidin expression and transcription without inducing the phosphorylation of 
Smad1/5/8 in primary hepatocytes, HepG2 cells or Hepa1-6 cells. Co-treatment with 
LDN-193189, an inhibitor of the BMP type I receptor, abrogated this hepcidin induction. 
Reporter assays using mutated reporters revealed the involvement of the BMP response 
element-1 (BMP-RE1) and signal transducers and activator of transcription (STAT)- and 
activator protein (AP)-1-binding sites in serum-induced hepcidin transcription in HepG2 
cells. Serum treatment induced the expression of the AP-1 components c-fos and junB 
in primary hepatocytes and HepG2 cells. Forced expression of c-fos or junB enhanced 
the response of hepcidin transcription to serum treatment. By contrast, expression of 
dominant negative (dn)-c-fos and dn-junB decreased hepcidin transcription. The present 
study reveals that serum contains factors stimulating hepcidin transcription. Basal BMP 
activity is essential for the serum-induced hepcidin transcription, although serum 
treatment does not stimulate the BMP pathway. The induction of c-fos and junB by 
serum treatment stimulates hepcidin transcription, through possibly cooperation with 
BMP-mediated signaling. Considering that AP-1 is induced by various stimuli, the 
present results suggest that hepcidin expression is regulated by more diverse factors 






Iron is essential for fundamental metabolic processes in cells and organisms. Iron 
homeostasis is strictly maintained through cellular and systemic systems. Cellular iron 
metabolism is regulated through iron-regulatory proteins that bind iron-responsive 
elements in regulated mRNAs. By contrast, systemic iron metabolism is mainly 
governed by the synthesis and secretion of the iron-regulating hormone hepcidin. 
Hepcidin is produced by liver parenchymal cells and orchestrates systemic iron fluxes 
and decreases plasma iron levels by binding to and degrading the iron exporter 
ferroportin on the surface of iron-releasing cells, especially on the basolateral membrane 
of enterocytes (Lee and Beutler, 2009; Hentze et al., 2010; Anderson et al., 2012). 
 
Hepcidin expression is transcriptionally regulated; bone morphogenetic protein (BMP), 
a member of the transforming growth factor-β (TGF-β) family, potently stimulates the 
process (Muckenthaler, 2008; Lee and Beutler, 2009; Hentze et al., 2010; Finberg, 
2013). Members of the TGF-β family, including BMP, TGF-β, and activin, elicit their 
activities through similar but distinct signal transduction pathways. Upon ligand binding, 
the receptor complexes phosphorylate carboxyl-terminal serines of receptor-regulated 
(R-) Smad; BMP induces the phosphorylation of Smad1/5/8, whereas TGF-β/activin do 
Smad2/3 phosphorylation. Phosphorylated R-Smad forms complexes with the common 
Smad, Smad4, and these translocate into the nucleus where they participate in the 
regulation of gene transcription (Miyazono et al., 2010; Massague, 2012; 
Sakaki-Yumoto et al., 2013). 
 
In addition to the BMP pathway, several other molecules, such as interleukin (IL)-6, 
IL-22, oncostatin M and testosterone, also regulate hepcidin transcription (Nemeth et al., 
2003; Kanda et al., 2009; Chung et al., 2010; Guo et al., 2013; Smith et al., 2013); other 





During the exploration of BMP-induced hepcidin expression, we noticed that serum 
starvation down-regulates hepcidin expression in hepatocytes. This observation 
prompted us to pursue the role of serum as a positive regulator in hepcidin expression. 
Here we show that serum stimulates hepcidin transcription via the following: an 
activator protein (AP)-1 binding site within the hepcidin promoter, which spans nt -133 
to nt -127 and was identified previously but was not characterized (Truksa et al., 2007); 
the signal transducers and activator of transcription (STAT)-binding site (STAT-BS), 
which spans nt -143 to nt -134; and the BMP response element 1 (BMP-RE1), which 
spans nt -155 to nt -150. Although serum treatment does not stimulate the BMP pathway, 
the basal BMP activity is indispensable for serum-induced hepcidin transcription. In 
addition, the AP-1 components c-fos and junB induced by serum treatment would be 
involved in the transcriptional activation. The present study extends our understanding 
of hepcidin expression. AP-1 is induced by various stimuli, such as stress, infections 
and inflammations, and certain stimuli that are mediated by cytokines and growth 
factors (Hess et al., 2004). Thus, the present results suggest that hepcidin is regulated by 
more factors than were previously considered. 
 
 
2. Materials & methods 
2.1. Materials 
The following reagents were purchased and used: BMP2 was from R & D Systems 
(Minneapolis, MN, USA); BMP6 was from GeneTex (Irvine, CA, USA); LDN-193189, 
an inhibitor for BMP type I receptor (Yu et al., 2008a) was from Stemgent (San Diego, 
CA, USA); rabbit polyclonal antibodies against phospho-Smad1 (Ser463/Ser465) / 
Smad5 (Ser463/Ser465) / Smad8 (Ser426/Ser428) (#9511) and p38 (#9212) were from 
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Cell Signaling Technology (Danvers, MA, USA); a mouse monoclonal antibody against 
Smad1 (A-4, sc-7965) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA); a 
rabbit monoclonal antibody against Smad1 (EP565Y, ab33902) and a mouse 
monoclonal antibody against β-actin (AC-15, ab6276) were from Abcam (Cambridge, 
MA, USA). 
 
2.2. Cell culture 
Animal experiments were approved by the Kyoto University Animal Experiment 
Committee. Primary rat hepatocytes were isolated by collagenase digestion of livers 
from male Sprague-Dawley rats aged 4 weeks. The livers were perfused from the portal 
vein to the incised inferior vena cava with calcium and magnesium-free (CMF) buffer 
(40 mM Hepes, pH 7.4, 120 mM NaCl, 5.4 mM KCl, 5.0 mM NaHCO3 and 5.6 mM 
glucose supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 250 
ng/mL amphotericin B) for 10 min at a rate of ~12 mL/min followed by perfusion with 
CMF buffer containing 0.05% collagenase (Wako, Osaka, Japan) for 10 min. 
Subsequently, hepatocytes were liberated into Hank’s buffered salt solution (HBSS), i.e., 
140 mM NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 0.81 mM 
MgSO4∙7H2O, 1.3 mM CaCl2, 4.2 mM NaHCO3 and 5.6 mM glucose supplemented 
with 100 U/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin B. 
After cell recovery by centrifugation at 50 × g for 2 min, the cells were washed with 
HBSS three times and were then resuspended in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics. Cells 
(>90% hepatocytes by microscopy) were seeded on collagen-coated plates at 1.5 
×105 cells per well in 12-well plates. Attached cells were subsequently used. HepG2 
hepatoma cells and Hepa1-6 hepatoma cells were cultured in DMEM with 10% 




2.3. RNA isolation and RT-quantitative PCR 
Total RNA was isolated from rat primary hepatocytes by using TRIZOL (Invitrogen, 
Grand Island, NY, USA) and cDNA was synthesized by the ABI high capacity cDNA 
reverse transcription kit (Applied Biosystems, Foster City, CA, USA), according to the 
manufacturers’ protocols. The cDNA that was reverse-transcribed from 5 ng of total 
RNA was used as a template for RT-quantitative PCR (RT-qPCR) as previously 
described (Asano et al., 2013). The oligonucleotide primers for RT-qPCR are as follows: 
5’-gatggcactcagcactgga-3’ and 5’-gctgcagctctgtagtctgtct-3’ for hepcidin, 
5’-gaacactggatggacgactg-3’ and 5’-acagacgggcatagatcaca-3’ for Smad4, and 
5’-cgtgttcctacccccaatgt-3’ and 5’-tgtcatcatacttggcaggtttc-3’ for 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). The Ct value was determined, and 
the abundance of gene transcripts was analyzed using the ∆∆Ct method and by 
normalizing against the Gapdh gene (Duran et al., 2005). 
 
2.4. Western blot 
Western blot analyses were performed as previously described (Funaba and Murakami, 
2008). The immunoreactive proteins were visualized using the ECL Select Western 




The DNA sequence that spans nt -2018 to nt -35 of the mouse hepcidin (Hamp1) 
promoter was amplified and cloned into a pGL4 basic vector that contained the firefly 
luciferase reporter (Hepcidin (-2018)-luc); nt +1 was defined as the translation initiation 
site. Reporter plasmids with deleted promoters or point mutations were prepared by a 
PCR-based method. The dominant negative (dn)-c-fos, which lacks region encoding 
amino acid 133 to amino acid 159 (Ransone et al., 1990), was also prepared by a 
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PCR-based method. The plasmids were verified by DNA sequencing. Expression 
vectors for c-fos, junB and dn-jun B were kindly provided by Dr. M. Hibi. 
 
2.6. Reporter assays 
HepG2 and Hepa1-6 hepatoma cells were transiently transfected with the described 
expression vectors, reporter construct and a plasmid expressing β-galactosidase 
(pCMV-βGal) with the use of the polyethylenimine Max reagent (Polysciences, 
Warrington, PA, USA) according to the manufacturer’s protocol. DNA transfection was 
performed in the absence of heat-inactivated FBS. Equal amounts of DNA, adjusted 
with empty vector, were transfected in each experiment. At 4 h post-transfection, cells 
were cultured with medium with or without heat-inactivated FBS for 24 h. Luciferase 
activity in the cell lysate was normalized to β-galactosidase activity. 
 
2.7. Statistical analyses 
Data are expressed as the mean ± standard error (SE). Data on gene expression were 
log-transformed to provide an approximation of a normal distribution before analysis. 
Differences between gene expression in the cells were examined using unpaired t-tests. 
Differences of P < 0.05 were considered significant. 
 
 
3. Results and discussion 
3.1. Serum stimulates hepcidin transcription in liver cells 
When effects of exogenous ligand are examined, cells are typically cultured with a 
reduced concentration of heat-inactivated FBS before and during ligand stimulation. 
During the analysis of BMP-induced hepcidin expression in rat primary hepatocytes, we 
reproducibly observed that serum starvation itself down-regulates hepcidin expression 
significantly (P < 0.05, Fig. 1A). The decreased expression levels of hepcidin were not 
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caused by a non-specific down-regulation of gene expression, because serum starvation 
did not affect Smad4 expression. These results suggest that serum has a stimulatory 
effect on hepcidin expression. Thus, we aimed to verify the up-regulation of hepcidin 
expression levels in response to serum treatment. Attached rat primary hepatocytes were 
cultured in the absence of heat-inactivated FBS followed by treatment with or without 
10% FBS. Consistent with the results on the effects of serum starvation (Fig. 1A), the 
serum treatment clearly increased expression of hepcidin but not Smad4 in primary 
hepatocytes (P < 0.01, Fig. 1B). 
 
Previous studies revealed that hepcidin expression is primarily increased by activation 
of the BMP pathway (Lee and Beutler, 2009; Hentze et al., 2010; Finberg, 2013). 
Especially, BMP6 principally regulates hepcidin transcription in livers; mice lacking 
BMP6 exhibited inappropriately low level of hepcidin and massive iron overload 
(Andriopoulos et al., 2009; Meynard et al., 2009). BMP2 is relatively heat-stable, and 
heat-inactivation of FBS for 30 min at 56°C did not decrease the bioactivity of BMP2 
(Ohta et al., 2005), although the stability of BMP6 in response to the heat treatment is 
unknown. Thus, it is possible that BMP or the related molecule(s) in heat-inactivated 
FBS is responsible for serum-induced hepcidin expression. To this end, we evaluated 
phosphorylated Smad1/5/8 in response to serum stimulation in primary hepatocytes 
because BMPs elicit their activities through the phosphorylation of carboxyl-terminal 
serines of Smad1/5/8 (Miyazono et al., 2010; Massague, 2012; Sakaki-Yumoto et al., 
2013). 
 
Serum treatment did not increase the phosphorylation levels of Smad1/5/8 in primary 
hepatocytes; rather, phosphorylated Smad1/5/8 levels tended to decrease with serum 
treatment, implying the presence of inhibitor(s) for the BMP pathway in serum (Fig. 1C, 
lanes 2-9). As expected, Smad1/5/8 was clearly phosphorylated within 1 h after BMP2 
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treatment in primary hepatocytes (Fig. 1C, lanes 10 and 11). Pre-treatment with 
LDN-193189 decreased phosphorylation levels of Smad1/5/8 (Fig. 1D) and abrogated 
serum-induced hepcidin expression (Fig. 1E). 
 
To explore serum-induced hepcidin expression in detail, experiments were next 
performed in HepG2 cells and Hepa1-6 cells. Consistent with the results from primary 
hepatocytes, serum treatment did not induce the phosphorylation of Smad1/5/8 in either 
HepG2 cells or Hepa1-6 cells (Fig. 2A). We next examined hepcidin transcription by 
luciferase-based reporter assays in HepG2 cells and Hepa1-6 cells; these cell lines are 
suitable to examine hepcidin transcription but not hepcidin expression at the mRNA 
level (Kanamori et al., 2014). Serum treatment increased the expression levels of 
hepcidin(-2018)-luc in HepG2 cells and Hepa1-6 cells (Fig. 2B), which indicated that 
serum-induced hepcidin expression is regulated at the level of transcription. In addition, 
pre-treatment with LDN-193189 decreased luciferase activity and blocked 
serum-induced hepcidin transcription (Fig. 2B). These results indicate that BMP activity 
is not further enhanced by serum treatment but that endogenous BMP activity is 
required for serum-induced hepcidin expression and transcription in liver cells. 
 
We also evaluated effects of BMP6 in heat-inactivated FBS on Smad1/5/8 
phosphorylation and hepcidin transcription in HepG2 cells and Hepa1-6 cells. Herrera 
and Inman (2009) reported that FBS contains ~300 pM of BMP6, which was 
determined by transcriptional activity of BMP-responsive reporter. Thus, it is estimated 
that the culture medium, i.e., DMEM with 10% FBS, contains ~30 pM of BMP6 that 
was heated for 30 min for 56°C. Significant induction of Smad1/5/8 phosphorylation 
and hepcidin transcription could not be detected in HepG2 cells and Hepa1-6 cells 
treated with below 30 pM of the heat-treated BMP6 (Fig. 2C and D). Taken failure of 
Smad1/5/8 phosphorylation in response to serum treatment in primary hepatocytes (Fig. 
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1C and D) with the inability to phosphorylate Smad1/5/8 and transactivate hepcidin by 
30 pM of the heat-treated BMP6 in live cell lines together, BMP in the FBS is not likely 
to explain serum-induced up-regulation of hepcidin expression. Previous studies also 
revealed that a BMP concentration greater than 100 pM is required to induce hepcidin 
expression (Truksa et al., 2006; Maes et al., 2010; Wu et al., 2012). 
 
3.2. Serum-induced hepcidin transcription is mediated via BMP-RE1, TRE 
and STAT-BS 
Previous studies revealed that the hepcidin promoter has two BMP responsive elements: 
BMP-RE1 (spanning nt -155 to nt -150) and BMP-RE2 (spanning nt -1678 to nt -1673) 
(Casanovas et al., 2009; Truksa et al., 2009). We performed reporter assays using a 
series of deleted reporters of mouse hepcidin promoter. The responsiveness to serum 
treatment was still detected by a deletion of BMP-RE2, although basal transcription was 
reduced and the extent of the increase in luciferase expression in response to serum 
treatment was decreased (Fig. 3A). The deletion of BMP-RE1 further decreased basal 
transcription and inhibited the responsiveness to serum treatment (Fig. 3A), which 
suggests an essential role of BMP-RE1 in serum-induced hepcidin transcription. 
Consistent with these results, reporter assays that used reporters with point mutations in 
BMP-RE1, BMP-RE2 or both revealed that serum-induced hepcidin transcription was 
inhibited in reporters containing mutations in BMP-RE1 but not BMP-RE2 (Fig. 3B). 
 
Serum treatment is known to induce the expression of AP-1 components, which 
stimulate transcription by binding to the TPA-responsive element (TRE) located in the 
transcriptional regulatory region of the gene (Shaulian and Karin, 2002; Hess et al., 
2004). The TRE consensus sequence is TGAG/CTCA (Shaulian and Karin, 2002; Hess et 
al., 2004), but the closely related sequence TGAGACA also binds to AP-1 and confers 
AP-1-mediated transcription (Kim et al., 1990). A search for the hepcidin gene 
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identified a possible TRE sequence from nt -133 to nt -127 (Fig. 4A). 
 
Truksa et al. (2007) reported the existence of the TRE sequence in the hepcidin gene 
and explored its function in IL-6 and BMP9-induced hepcidin transcription by using a 
reporter plasmid containing the hepcidin promoter with TRE mutations. However, to 
create the "TRE mutated reporter" they mutated sequence outside of the core TRE 
sequence (TGAG/CTCA) (Truksa et al., 2007), and therefore the role of TRE was not 
strictly evaluated in their study. Additionally, adjacent to the TRE sequence, a STAT-BS 
sequence spans nt -143 to nt -134 (Fig. 4A). Although the STAT-BS sequence has been 
reported to function in IL-6-induced transcription (Wrighting and Andrews, 2006), 
mutations in the STAT-BS in mouse hepcidin (Hamp1) did not affect the responsiveness 
to IL-6 (Truksa et al., 2007). In the present study, we prepared reporter plasmids with 
mutated core TRE sequence (mTRE), STAT-BS sequence (mSTAT) or both (mSTAT, 
TRE) by introducing point mutations at distal sites from the mutual elements (Fig. 4B). 
In this case, we used a reporter plasmid with a shorter hepcidin promoter, 
hepcidin(-270)-luc, as a wild-type plasmid to evaluate serum responsiveness (Fig. 3A).  
 
Serum-induced hepcidin transcriptional activation was decreased when the TRE or 
STAT-BS was mutated (Fig. 4C), and the double mutations completely abrogated 
serum-induced hepcidin transcription. In addition, mutations in the TRE decreased basal 
transcription levels of hepcidin. These results suggest that both the TRE and STAT-BS 
are required for full activation of hepcidin transcription induced by serum; especially, 
TRE is essential for the basal transcription of hepcidin. 
 
Verga Falzacappa et al. (2007) identified a possible AP-1 binding site but not the TRE in 
the human hepcidin gene, which extends from nt -313 to nt -304, by use of the 
nucleotide database on putative transcription factor binding sites. The nucleotide 
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database did not indicate the corresponding region of mouse hepcidin gene (Hamp1), nt 
-292 to nt -283, as a putative AP-1 binding site (Fig. 5A). Nevertheless, we examined 
the role of the region spanning from nt -292 to nt -283 by use of hepcidin(-581)-luc as a 
wild-type plasmid. The responsiveness to serum was not changed by the mutations of 
the region (Fig. 5B). The results are consistent with those that deletion of nt -581 to nt 
271 did not affect hepcidin transcription in response to serum (Fig. 3A). Thus, we 
conclude that the putative AP-1 site suggested by Verga Falzacappa et al. (2007) is not 
functional for serum-induced transcription of mouse hepcidin. 
 
3.3. Serum induces c-fos and junB expression in liver cells, which is 
responsible for hepcidin transcription via TRE and STAT-BS 
We examined the induction of AP-1 in response to serum treatment in primary 
hepatocytes (Fig. 6A) and HepG2 cells (Fig. 6B). The time-course changes that 
occurred during serum stimulation were similar between the two cell types but were 
different among the genes analyzed; c-fos expression was transiently induced within 30 
min after serum treatment, and c-fos expression levels returned to basal levels at 1.5 h 
after serum treatment in primary hepatocytes and at 2 h in HepG2 cells. Expression 
levels of junB significantly higher in cells treated with serum at 1 h of serum treatment 
in primary hepatocytes and from 0.5 h to 4 h in HepG2 cells. In contrast, serum 
treatment did not significantly affect c-jun expression in primary hepatocytes, although 
it slightly but significantly increased from 0.5 to 4 h in HepG2 cells. 
 
Considering that serum treatment stimulated hepcidin expression and transcription in 
primary hepatocytes and HepG2 cells, expression of c-fos and junB but not c-jun may 
be involved in serum-induced hepcidin transcription. Thus, we explored the effects of 
the forced expression of c-fos and junB were examined (Fig. 7). Expression of c-fos 
alone increased transcription of hepcidin, and it also increased serum-induced hepcidin 
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transcription. The responsiveness to serum also increased with junB expression, 
although junB expression alone did not stimulate hepcidin transcription. Mutations of 
either the STAT-BS or TRE sequences decreased hepcidin transcription, irrespective of 
serum stimulation. The effects of the TRE mutations were more remarkable, but the 
reporters still responded to serum treatment. Double mutations in both the STAT-BS and 
TRE sequences completely inhibited hepcidin transcription. 
 
We further examined effects of expression of dn-c-fos or dn-junB on hepcidin 
transcription (Fig. 8). Basal transcription of hepcidin was decreased by expression of 
dn-c-fos or dn-junB. In addition, the extent of the increase in luciferase activity in 
response to serum treatment was smaller in cells expressing dn-c-fos or dn-junB than in 
those expressing empty vector. 
 
Here, we showed that withdrawal of heat-inactivated FBS decreased the expression of 
hepcidin in primary hepatocytes and that serum treatment increased hepcidin expression 
and transcription (and vice versa) in primary hepatocytes, HepG2 cells and Hepa1-6 
cells. We also demonstrated that serum treatment does not stimulate the BMP pathway 
but basal BMP activity is required for hepcidin induction through the BMP-RE1 region 
of its promoter. The serum induced expression of c-fos and junB, and both the TRE and 
STAT-BS sequences within the hepcidin promoter are essential for serum-induced 
transcription. AP-1 enhances the transcription of the α2-macroglobulin gene through 
complex formation with STAT3 (Ginsberg et al., 2007). The requirement of adjacent 
STAT-BS and TRE sequences suggests the cooperative role of AP-1 and STAT3 in 
AP-1-mediated hepcidin transcription, similar to that for the α2-macroglobulin gene. 
 
Hepcidin transcription, via both STAT-BS and TRE regulation, may be elicited by some 
cytokines. For example, oncostatin M, a stimulator of hepcidin expression (Kanda et al., 
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2009; Chung et al., 2010), can induce the expression of AP-1 components (Botelho et 
al., 1998). Not only JAK inhibition but also MEK1/2 inhibition blocked oncostatin 
M-mediated hepcidin expression (Kanda et al., 2009; Chung et al., 2010); JAK 
phosphorylates and activates STAT (Ihre, 2001), and MEK1/2 is a MAPK kinase and an 
upstream molecule that induces AP-1 components (Shaulian and Karin, 2002). 
 
The present study reveals the requirements of BMP-RE1, TRE and STAT-BS for the full 
induction of hepcidin transcription by serum treatment; BMP-RE1 is essential for the 
responsiveness to serum, although BMP activity is not enhanced by serum. In view of a 
central role of the BMP pathway in hepcidin transcription, AP-1 possibly accelerates 
hepcidin transcription through enhancement of basal BMP activity. Previous studies 
revealed AP-1 cooperatively enhanced TGF-β-mediated transcription through activated 
Smad3 and Smad4 (Zhang et al., 1998; Wong et al., 1999; Funaba et al., 2006; 
Busnadiego et al., 2013), but at present, no direct evidence is available on the role of 
AP-1 in BMP-mediated signaling. Members of the Jun family physically interact with 
Smad4 (Liberati et al., 1999), a common Smad that transmits both TGF-β and BMP 
signals (Miyazono et al., 2010; Massague, 2012; Sakaki-Yumoto et al., 2013). In 
addition, a liver-specific disruption of Smad4 decreased expression of hepcidin in mice, 
and overexpression of Smad4 increased transcription of hepcidin in Hepa1-6 cells 
(Wang et al., 2005), which indicates the involvement of Smad4 in hepcidin expression. 
To clarify the role of AP-1 in BMP signaling, the effects of exogenous BMP should be 
examined in future studies. 
 
During the preparation of this manuscript, the effect of serum treatment on hepcidin 
transcription was reported (Shanmugam and Cherayil, 2013). These researchers showed 
that heat-inactivated FBS treatment increased the phosphorylation levels of Smad1/5/8 
and hepcidin mRNA levels in HepG2 cells, which were blocked by co-treatment with 
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dorsomorphin, an inhibitor of the BMP type I receptor, as well as AMPK (Zhou et al., 
2001; Yu et al., 2008b). These authors concluded that BMP or BMP-related proteins in 
heat-inactivated FBS are responsible for the serum-induced hepcidin mRNA changes, 
and these researchers’ results on serum-induced hepcidin expression are consistent with 
those of the present study. However, the underlying mechanism clearly contrasts with 
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Fig. 1. Modulation of hepcidin expression levels by serum concentrations in rat 
primary hepatocytes 
(A) Attached rat primary hepatocytes were cultured in the presence or absence of 
heat-inactivated FBS for 12 h. Hepcidin expression was examined by RT-qPCR and 
expressed as ratios to Gapdh, with the level set to 1 in cells cultured in the presence of 
heat-inactivated FBS. Data shown are the mean ± SE (n = 3). *: P < 0.05, vs. cells 
treated with 10% FBS. (B) Attached rat primary hepatocytes were cultured in the 
absence of heat-inactivated FBS for 4 h, followed by culturing with or without 10% 
heat-inactivated FBS for 12 h. Hepcidin expression was examined by RT-qPCR and is 
expressed as ratios to Gapdh, with the level set to 1 in cells treated without FBS. Data 
shown are the mean ± SE (n = 4). **: P < 0.01, vs. cells treated without serum. (C) 
Attached rat primary hepatocytes were cultured in the presence or absence of 
heat-inactivated FBS for the indicated time. Phosphorylated Smad1/5/8, Smad1 and p38 
were examined by Western blot analysis. As a positive control, rat primary hepatocytes 
were also treated with BMP2 (4 nM) for 1 h. (D and E) Attached rat primary 
hepatocytes were treated with or without LDN-193189 for 20 min followed by 
treatment with or without 10% heat-inactivated FBS for 1 h (D) or 12 h (E). (D) 
Phosphorylated Smad1/5/8, Smad1 and p38 were examined by Western blot analysis. 
(E) Hepcidin expression was examined by RT-qPCR and is expressed as ratios to Gapdh, 
with the level set to 1 in cells treated without LDN-193189 and FBS. Data shown are 
the mean ± SE (n = 4). **: P < 0.01, vs. cells treated with the respective reagent 
(vehicle or LDN-193189) but without serum. ‡: P < 0.01, vs. cells treated with vehicle 
and serum. 
 
Fig. 2. Role of endogenous BMP activity in serum-induced hepcidin expression 
(A and C) HepG2 cells and Hepa1-6 cells were cultured in the absence of 
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heat-inactivated FBS for 4 h. (A) After pre-treatment with or without LDN-193189 for 
20 min, cells were cultured with or without 10% heat-inactivated FBS for 1 h. (C) Cells 
were treated with or without various concentration of BMP6, which was heated for 30 
min at 56°C, for 1 h. Concentration of the treated BMP6 is as follows; lanes 2 and 9: 
0.24 pM, lanes 3 and 10: 1.2 pM, lanes 4 and 11: 6 pM, lanes 5 and 12: 30 pM, lanes 6 
and 13: 150 pM. As a positive control, cells were treated with 4 nM BMP6 (lanes 7 and 
14). (A and C) Phosphorylated Smad1/5/8, Smad1 and β-actin were examined by 
Western blot analysis. (B and D) After transfection with Hepcidin(-2018)-luc and 
CMV-βGal, HepG2 cells and Hepa1-6 cells were cultured in the absence of 
heat-inactivated FBS for 4 h. (B) After pre-treatment with or without LDN-193189 for 
20 min, cells were cultured with or without 10% heat-inactivated FBS for 24 h. (D) 
Cells were treated with or without 30 pM BMP6, which was heated for 30 min at 56°C, 
for 24 h. As a positive control, cells were treated with 4 nM BMP6. (B and D) 
Luciferase activity was normalized to β-galactosidase activity, and the luciferase 
activity in cells cultured in the absence of LDN-193189 and FBS was set to 1. Data 
were expressed as the mean ± SE from a representative experiment (n = 3). 
 
Fig. 3. Role of BMP-RE in serum-induced hepcidin expression 
After transfection with the indicated reporter plasmid and CMV-βGal, HepG2 cells 
were cultured in the absence of heat-inactivated FBS for 4 h. After pre-treatment with or 
without LDN-193189 for 20 min, cells were cultured with or without 10% 
heat-inactivated FBS for 24 h. Luciferase activity was normalized to β-galactosidase 
activity, and the luciferase activity in cells that were cultured in the absence of FBS and 
were transfected with hepcidin(-2018)-luc was set to 1. Data were expressed as the 
mean ± SE from a representative experiment (n = 3). Hepcidin transcription was 
examined by the use of reporter genes with series of deletions (A) or a reporter gene 
with point mutations in BMP-RE1 and -RE2 (B). BMP-RE1 (GGCGCC) was mutated 
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to aGaaCC, and BMP-RE2 (GGCGCC) was mutated to tcaGCC; the mutated 
nucleotides are shown in small characters. 
 
Fig. 4. TRE in the hepcidin promoter 
(A) Nucleotide sequence of the hepcidin promoter around TRE. Possible TRE sequence 
is indicated by a box, and BMP-RE1 and STAT-BS are indicated by a double underline 
and a dotted underline, respectively. (B) Mutations in STAT-BS and TRE. TRE and 
STAT-BS are indicated by a box and a dotted underline, respectively. The mutated 
nucleotides are shown in small characters. (C) The role of TRE and STAT-BS in 
serum-induced hepcidin transcription. After transfection with the indicated reporter 
plasmid and CMV-βGal, HepG2 cells were cultured in the absence of heat-inactivated 
FBS for 4 h followed by culture with or without 10% heat-inactivated FBS for 24 h. 
Luciferase activity was normalized to β-galactosidase activity, and the luciferase 
activity in cells that were cultured in the absence of FBS and were transfected with 
hepcidin(-270)-luc was set to 1. Data were expressed as the mean ± SE from a 
representative experiment (n = 3). 
 
Fig. 5. Role of a putative AP-1 binding site in serum-induced hepcidin expression 
(A) Nucleotide sequence of human putative AP-1 binding site and the corresponding 
region in mouse and rat hepcidin promoter. (B) The role of the putative AP-1 binding 
site in serum-induced hepcidin transcription. After transfection with the indicated 
reporter plasmid and CMV-βGal, HepG2 cells were cultured in the absence of 
heat-inactivated FBS for 4 h followed by culture with or without 10% heat-inactivated 
FBS for 24 h. Luciferase activity was normalized to β-galactosidase activity, and the 
luciferase activity in cells that were cultured in the absence of FBS and were transfected 
with hepcidin(-581)-luc was set to 1. Data were expressed as the mean ± SE from a 
representative experiment (n = 3). The corresponding region to human putative AP-1 
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binding site (TGTGACATCA) was mutated to TGTGttATCA; the mutated nucleotides 
are shown in small characters. 
 
Fig. 6. The induction of AP-1 components in response to serum stimulation 
Primary hepatocytes (A) and HepG2 cells (B) were cultured in the absence of 
heat-inactivated FBS for 4 h followed by culturing with or without 10% heat-inactivated 
FBS for the indicated time. Expression of AP-1 components such as c-fos, c-jun and 
junB was examined by RT-qPCR and expressed as ratios to Gapdh, with the level in 
cells at time = 0 set to 1. Data shown are the mean ± SE (n = 4). * and **: P < 0.05 and 
P < 0.01, respectively, vs. cells treated without serum at the same time point. 
 
Fig. 7. Enhancement of hepcidin transcription by AP-1 via TRE 
The role of AP-1 components in serum-induced hepcidin transcription. After 
transfection with the indicated AP-1 component expression vector and reporter plasmid, 
and CMV-βGal, HepG2 cells were cultured in the absence of heat-inactivated FBS for 4 
h followed by culturing with or without 10% heat-inactivated FBS for 24 h. Luciferase 
activity was normalized to β-galactosidase activity, and the luciferase activity was set to 
1 in cells that were cultured in the absence of exogenous AP-1 components and FBS and 
were transfected with hepcidin(-270)-luc. Data were expressed as the mean ± SE from a 
representative experiment (n = 3). 
 
Fig. 8. Inhibition of hepcidin transcription by dn-c-fos and dn-junB 
After transfection with the indicated dominant negative form of the AP-1 component 
expression vector and reporter plasmid, and CMV-βGal, HepG2 cells were cultured in 
the absence of heat-inactivated FBS for 4 h followed by culturing with or without 10% 
heat-inactivated FBS for 24 h. Luciferase activity was normalized to β-galactosidase 
activity, and the luciferase activity was set to 1 in cells that were cultured in the absence 
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of exogenous AP-1 components and FBS and were transfected with hepcidin(-270)-luc. 
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